文献詳細
Focus 泌尿器科の未来を拓くバイオ技術
文献概要
要旨 非筋層膀胱癌に対するBCG注入療法が5割もの再発予防効果を有する。その一方で浸潤癌に対する治療法は化学療法の進歩と工夫にもかかわらず,膀胱癌の10年生存率はおしなべると5割程度にとどまる。膀胱癌は発生と進展に遺伝子異常がかかわることが指摘されており,化学療法の反応性が不均一である原因であるとも考えられる。既存の治療法を凌駕する治療法の発見のきっかけとして分子標的療法は膀胱癌をはじめとした尿路上皮腫瘍でも現状で欧米を中心として臨床治験が進行中である。膀胱癌で現在まで研究の進んだ癌遺伝子としてはEGFR,MDM2,Ras,サイクリンD1などがあり,癌抑制遺伝子としてはp53などが知られている。本稿では膀胱癌の分子標的療法,特に核内レセプターを標的とする治療の可能性についてふれる。
参考文献
1)Panigrahy D, Shen LQ, Kieran MW, et al:Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs 12:1925-1937, 2003
2)Mueller E, Sarraf P, Tontonoz P, et al:Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1:465-470, 1998
3)Le Guevel R, Oger F, Lecorgne A, et al:Identification of small molecule regulators of the nuclear receptor HNF4alpha based on naphthofuran scaffolds. Bioorg Med Chem 17:7021-7030, 2009
4)Lippman SM and Lotan R:Advances in the development of retinoids as chemopreventive agents. J Nutr 130:479S-482S, 2000
5)Amaral JD, Sola S, Steer CJ, et al:Role of nuclear steroid receptors in apoptosis. Curr Med Chem 16:3886-3902, 2009
6)Chinetti G, Fruchart JC and Staels B:Peroxisome proliferator-activated receptors(PPARs):nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49:497-505, 2000
7)Carmo-Fonseca M and Carvalho C:Nuclear organization and splicing control. Adv Exp Med Biol 623:1-13, 2007
8)Wolf IM, Heitzer MD, Grubisha M, et al:Coactivators and nuclear receptor transactivation. J Cell Biochem 104:1580-1586, 2008
9)Stefani G and Slack F:MicroRNAs in search of a target. Cold Spring Harb Symp Quant Biol 71:129-134, 2006
10)Wiemer EA:The role of microRNAs in cancer:no small matter. Eur J Cancer 43:1529-1544, 2007
11)Yoshimura R, Matsuyama M, Hase T, et al:The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells. Int J Mol Med 12:861-865, 2003
12)Zhang GY, Ahmed N, Riley C, et al:Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer 92:113-119, 2005
13)Corton JC, Anderson SP and Stauber A:Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol 40:491-518, 2000
14)Eibl G, Reber HA, Hines OJ, et al:COX and PPAR:possible interactions in pancreatic cancer. Pancreas 29:247-253, 2004
15)Segawa Y, Yoshimura R, Hase T, et al:Expression of peroxisome proliferator-activated receptor(PPAR)in human prostate cancer. Prostate 51:108-116, 2002
16)Yoshimura R, Matsuyama M, Segawa Y, et al:Expression of peroxisome proliferator-activated receptors(PPARs)in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer 104:597-602, 2003
17)Leibovici D, Grossman HB, Dinney CP, et al:Polymorphisms in inflammation genes and bladder cancer:from initiation to recurrence, progression, and survival. J Clin Oncol 23:5746-5756, 2005
18)Fauconnet S, Lascombe I, Chabannes E, et al:Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem 277:23534-23543, 2002
19)Dominick MA, White MR, Sanderson TP, et al:Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist:evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol 34:903-920, 2006
20)Guan YF, Zhang YH, Breyer RM, et al:Expression of peroxisome proliferator-activated receptor gamma(PPARgamma)in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1:330-339, 1999
21)Miyamoto H, Yang Z, Chen YT, et al:Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 99:558-568, 2007
掲載誌情報